New drug combo aims to control aggressive bone cancer in young patients
NCT ID NCT05019703
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, atezolizumab and cabozantinib, in 40 adolescents and young adults (ages 12 and up) with osteosarcoma that has come back or spread. Atezolizumab helps the immune system attack cancer cells, while cabozantinib blocks enzymes that help tumors grow. The goal is to see if this combination can slow or stop the cancer from getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glow-in-the-Dark dye could help surgeons find hidden lung cancer in teens
- Desperate hope: single patient gets custom RNA therapy for returning bone cancer
- Targeted drug shows promise for kids with tough cancers
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New drug targets tough childhood cancers with genetic flaws
- New combo therapy offers hope for tough bone cancer